BC Extra | Nov 16, 2019
Company News

Nov. 15 Company Quick Takes: Qiagen continues climb after confirming takeout offers; plus Fetroja, selumetinib, PharmAbcine, semaglutide

Qiagen confirms acquisition interest  Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Friday it is reviewing its strategic alternatives after receiving several “non-binding indications of interest for the acquisition” of the diagnostics company. Since acquisition rumors emerged Wednesday,...
BC Extra | Jul 1, 2019
Company News

Long wait cost Pfizer until BEACON data clinched Array deal

By waiting for a crucial clinical readout that arrived in May 2019, Pfizer watched Array's stock price climb for two years, eventually paying a takeout price that was well over four times the biotech's value...
BC Innovations | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BC Extra | Jun 17, 2019
Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
BC Innovations | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
BC Innovations | Mar 25, 2019
Distillery Therapeutics

IL-17RD or inhibition of ZEB1 to sensitize lung cancer to MEK inhibition

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest IL-17RD or blocking ZEB1 via miR-200 expression or HDAC inhibition could sensitize lung cancer to MEK inhibitors. In tumor samples from...
BC Week In Review | Feb 8, 2019
Clinical News

Array reports updated Phase III OS data for triple combo mCRC therapy

Array BioPharma Inc. (NASDAQ:ARRY) reported updated data from the safety lead-in portion of the Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and Erbitux cetuximab led to a median overall survival...
BioCentury | Jan 5, 2019

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Innovations | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
BC Week In Review | Aug 3, 2018
Clinical News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals July 26, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended...
Items per page:
1 - 10 of 238